Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

Metabolic Changes Induced by Dapagliflozin, an SGLT2 Inhibitor, in Japanese Patients with Type 2 Diabetes Treated by Oral Anti-diabetic Agents: A Randomized, Clinical Trial

(2022) Kayo Horibe et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin

(2022) Yi-Hong Zeng et al.   Scientific Reports

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

(2021) Suetonia C Palmer et al.   BMJ-British Medical Journal

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

(2021) Haleh Chehrehgosha et al.   Diabetes Therapy

Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis

(2021) Chloe Wong et al.   Frontiers in Endocrinology

Body Composition Methods in Adults with Type 2 Diabetes or at Risk for T2D: a Clinical Review

(2021) Nadia Markie Sneed et al.   Current Diabetes Reports

Association of Body Composition with Type 2 Diabetes: A Retrospective Chart Review Study

(2021) Chia-Ling Lin et al.   International Journal of Environmental Research and Public Health

Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study

(2021) Satilmis Bilgin et al.   IRISH JOURNAL OF MEDICAL SCIENCE

Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus

(2021) Vaneza Lira W. Wolf et al.   Nutrition & Diabetes

Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials

(2021) Qiong Wei et al.   Frontiers in Endocrinology

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

(2020) Rory J. McCrimmon et al.   DIABETOLOGIA

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial

(2020) Eugene Han et al.   Journal of Clinical Medicine

Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study

(2020) Tomoe Kinoshita et al.   Journal of Diabetes Investigation

Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study

(2020) Hirotatsu Nakaguchi et al.   Journal of Diabetes Investigation

Sodium–Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?

(2020) Adrian Post et al.   Journal of Clinical Medicine

Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis

(2020) Shintaro Sakurai et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients　― A Randomized Controlled Trial ―

(2020) Hiroyuki Kayano et al.   CIRCULATION JOURNAL

Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments

(2020) Mina Wang et al.   Frontiers in Endocrinology

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity

(2019) Maria J. Pereira et al.   DRUGS

Associations of BMI, waist circumference, body fat, and skeletal muscle with type 2 diabetes in adults

(2019) T. S. Han et al.   ACTA DIABETOLOGICA

Body composition changes in diabetes and aging

(2019) Mohammed E. Al-Sofiani et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Sarcopenia

(2019) Alfonso J Cruz-Jentoft et al.   LANCET

Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report

(2019) Megumi Yasuda et al.   Journal of Diabetes Investigation

Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial

(2019) Hajime Yamakage et al.   Journal of Diabetes Investigation

Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study

(2018) Yuya Tsurutani et al.   DIABETES OBESITY & METABOLISM

Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease

(2018) Masanori Shimizu et al.   DIABETES OBESITY & METABOLISM

Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies

(2018) John A. Batsis et al.   Nature Reviews Endocrinology

Ipragliflozin, an SGLT 2 Inhibitor, Reduces Body Weight and Fat Mass, but not Muscle Mass, in Japanese Type 2 Diabetic Patients Treated with Insulin: A Randomized Clinical Trial

(2018) Hideka Inoue et al.   Journal of Diabetes Investigation

Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events

(2015) Daisuke Yabe et al.   Expert Opinion On Drug Safety

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2013) J. Bolinder et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes: The Korean Sarcopenic Obesity Study (KSOS)

(2010) T. N. Kim et al.   DIABETES CARE

Abdominal Subcutaneous and Visceral Adipose Tissue and Insulin Resistance in the Framingham Heart Study

(2010) Sarah R. Preis et al.   Obesity